Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

NCT06976853 on ClinicalTrials.gov · last registry update 2026-06-05

Recruiting now, toward 60 participants. Due to report May 2028. Sponsors move these dates routinely; any movement since this site started watching is listed below.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Washington University School of Medicine
Sponsor type: Other
Enrollment: 60
Started: 2025-05-13
Primary completion: 2028-05 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proportion and number of participants who have treatment emergent adverse events, serious adverse events, discontinuation of study intervention due to adverse events and injection-site reactions by CTCAE v4.0

Conditions studied

Crohn Disease (CD)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.